Tecentriq IV infusion 840mg, containing atezolizumab (genetical recombination), is an injectable drug manufactured by Chugai Pharmaceutical. With YJ code 4291441A2020, this 840mg in 14mL per bottle formulation is used for treating various cancers such as non-small cell lung cancer, small cell lung cancer, and hepatocellular carcinoma.
Tecentriq IV infusion 840mg
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →